MA47575A - Composés inhibiteurs d'oga monocyclique - Google Patents
Composés inhibiteurs d'oga monocycliqueInfo
- Publication number
- MA47575A MA47575A MA047575A MA47575A MA47575A MA 47575 A MA47575 A MA 47575A MA 047575 A MA047575 A MA 047575A MA 47575 A MA47575 A MA 47575A MA 47575 A MA47575 A MA 47575A
- Authority
- MA
- Morocco
- Prior art keywords
- monocyclic
- inhibitor compounds
- oga inhibitor
- oga
- compounds
- Prior art date
Links
- 229940126137 O-GlcNAcase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16204840 | 2016-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47575A true MA47575A (fr) | 2020-01-01 |
Family
ID=57570524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047575A MA47575A (fr) | 2016-12-16 | 2017-12-15 | Composés inhibiteurs d'oga monocyclique |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200079766A1 (fr) |
| EP (1) | EP3555087A1 (fr) |
| JP (1) | JP2020503298A (fr) |
| CN (1) | CN110300752A (fr) |
| AU (1) | AU2017378186A1 (fr) |
| CA (1) | CA3045957A1 (fr) |
| MA (1) | MA47575A (fr) |
| WO (1) | WO2018109202A1 (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017003658B1 (pt) | 2014-08-28 | 2022-12-06 | Asceneuron Sa | Composto, mistura, método para inibição de uma glicosidase, e, composição farmacêutica |
| AU2017222964B2 (en) | 2016-02-25 | 2020-01-02 | Asceneuron S. A. | Glycosidase inhibitors |
| US11612599B2 (en) | 2016-02-25 | 2023-03-28 | Asceneuron Sa | Glycosidase inhibitors |
| EP3419976B1 (fr) | 2016-02-25 | 2021-04-07 | Asceneuron SA | Sels d'addition d'acide de dérivés de pipérazine |
| EP3585783A2 (fr) | 2016-02-25 | 2020-01-01 | Asceneuron SA | Inhibiteurs de la sulfoximine glycosidase |
| AR110747A1 (es) * | 2017-01-27 | 2019-05-02 | Lilly Co Eli | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo |
| EP3585790A1 (fr) * | 2017-02-27 | 2020-01-01 | Janssen Pharmaceutica NV | Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga |
| EP3672959A1 (fr) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Inhibiteurs linéaires de la glycosidase |
| US11459324B2 (en) | 2018-03-14 | 2022-10-04 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors |
| AU2019234759C1 (en) * | 2018-03-14 | 2025-02-06 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors |
| EP3810612A1 (fr) * | 2018-06-20 | 2021-04-28 | Janssen Pharmaceutica NV | Composés inhibiteurs d'oga |
| JP2021528413A (ja) * | 2018-06-20 | 2021-10-21 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｏｇａ阻害化合物 |
| AU2019289966A1 (en) * | 2018-06-20 | 2020-12-17 | Janssen Pharmaceutica Nv | OGA inhibitor compounds |
| JP2021528412A (ja) * | 2018-06-20 | 2021-10-21 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｏｇａ阻害化合物 |
| CN112469476B (zh) * | 2018-07-31 | 2024-07-16 | 伊莱利利公司 | 5-甲基-4-氟-噻唑-2-基化合物 |
| EP3841093B1 (fr) | 2018-08-22 | 2023-06-21 | Asceneuron SA | Sels d'addition d'acide de succinate et de fumarate de dérivés de pipérazine en tant qu'inhibiteurs de glycosidase |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
| WO2020039028A1 (fr) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Inhibiteurs de tétrahydro-benzoazépine glycosidase |
| US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
| IL315564A (en) * | 2018-09-19 | 2024-11-01 | Biogen Ma Inc | O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors |
| TWI716107B (zh) * | 2018-09-26 | 2021-01-11 | 美商美國禮來大藥廠 | 6-氟-2-甲基苯并[d]噻唑-5-基化合物 |
| AR117252A1 (es) * | 2018-12-05 | 2021-07-21 | Biogen Ma Inc | Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de morfolinilo, piperazinilo, oxazepanilo y diazepanilo |
| JP7504898B2 (ja) * | 2019-02-04 | 2024-06-24 | バイオジェン・エムエイ・インコーポレイテッド | 二環式エーテルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤 |
| EP3935055A1 (fr) | 2019-03-08 | 2022-01-12 | Biogen MA Inc. | Inhibiteurs d'azétidinyl 0-glyc0pr0téin-2-acétamid0-2-désoxy-3-d-gluc0pyran0sidase |
| CA3160627A1 (fr) | 2019-11-06 | 2021-05-14 | Yuhan Corporation | Composes de pyrrolidine et de piperidine |
| WO2021094312A1 (fr) | 2019-11-11 | 2021-05-20 | Janssen Pharmaceutica Nv | Composés inhibiteurs d'oga contenant de la pyrrolidine et de la bicyclohétéroaryle |
| BR112023002013A2 (pt) * | 2020-08-03 | 2023-05-02 | Biogen Ma Inc | Formas cristalinas de um inibidor de o-glicoproteína-2-acetamido-2-desóxi-3-d-glucopiranosidase |
| KR102533471B1 (ko) * | 2020-11-23 | 2023-05-19 | (주) 메디프론디비티 | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 |
| WO2024081775A1 (fr) | 2022-10-14 | 2024-04-18 | Eli Lilly And Company | Synthèse de composés 6-fluoro-2-méthylbenzo[d] thiazol-5-yle |
| WO2025247394A1 (fr) * | 2024-05-31 | 2025-12-04 | 纽欧申医药(上海)有限公司 | Composé hétérocyclique contenant de l'azote, composition pharmaceutique de celui-ci et utilisation associée |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1595923A1 (de) * | 1965-02-20 | 1969-11-27 | Merck Ag E | 1-Aralkyl-4-(thiazolyl-2)-piperazine und Verfahren zu ihrer Herstellung |
| EP0636130A1 (fr) | 1992-04-15 | 1995-02-01 | Merck Sharp & Dohme Ltd. | Composes azacycliques |
| US6982259B2 (en) | 2002-04-30 | 2006-01-03 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
| MX2008011968A (es) | 2006-03-31 | 2008-10-01 | Astrazeneca Ab | Compuestos biciclicos de bencimidazol y su uso como potenciadores del receptor metabotropico de glutamato. |
| WO2008012623A1 (fr) | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Composés de benzimidazolyle constituant des potentialisateurs du sous-type de récepteur de glutamate mglur2 |
| GB201103526D0 (en) * | 2011-03-02 | 2011-04-13 | Summit Corp Plc | Selective glycosidase inhibitors and uses thereof |
| ES2723883T3 (es) * | 2013-03-14 | 2019-09-03 | Merck Patent Gmbh | Inhibidores de glicosidasa |
| BR112017003658B1 (pt) * | 2014-08-28 | 2022-12-06 | Asceneuron Sa | Composto, mistura, método para inibição de uma glicosidase, e, composição farmacêutica |
| US10913733B2 (en) | 2015-12-18 | 2021-02-09 | Alectos Therapeutics Inc. | Substituted piperidines thiazolyl acetamides as glycosidase inhibitors and uses thereof |
| AU2017222964B2 (en) | 2016-02-25 | 2020-01-02 | Asceneuron S. A. | Glycosidase inhibitors |
| EP3419976B1 (fr) | 2016-02-25 | 2021-04-07 | Asceneuron SA | Sels d'addition d'acide de dérivés de pipérazine |
| US11612599B2 (en) | 2016-02-25 | 2023-03-28 | Asceneuron Sa | Glycosidase inhibitors |
-
2017
- 2017-12-15 CN CN201780086727.8A patent/CN110300752A/zh active Pending
- 2017-12-15 US US16/469,701 patent/US20200079766A1/en not_active Abandoned
- 2017-12-15 AU AU2017378186A patent/AU2017378186A1/en not_active Abandoned
- 2017-12-15 WO PCT/EP2017/083136 patent/WO2018109202A1/fr not_active Ceased
- 2017-12-15 MA MA047575A patent/MA47575A/fr unknown
- 2017-12-15 EP EP17816832.4A patent/EP3555087A1/fr not_active Withdrawn
- 2017-12-15 CA CA3045957A patent/CA3045957A1/fr not_active Abandoned
- 2017-12-15 JP JP2019531974A patent/JP2020503298A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018109202A1 (fr) | 2018-06-21 |
| CN110300752A (zh) | 2019-10-01 |
| US20200079766A1 (en) | 2020-03-12 |
| AU2017378186A1 (en) | 2019-06-13 |
| JP2020503298A (ja) | 2020-01-30 |
| CA3045957A1 (fr) | 2018-06-21 |
| EP3555087A1 (fr) | 2019-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125826T1 (el) | Ενωσεις αναστολεις της βητα-λακταμασης | |
| MA47576A (fr) | Composés inhibiteurs d'oga bicyclique | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| MA52939A (fr) | Composés inhibiteurs d'oga | |
| DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
| MA52942A (fr) | Composés inhibiteurs d'oga | |
| IL263586A (en) | Inhibitors of the menin-mll interaction | |
| EP3558322A4 (fr) | Composés benzyl-amide phosphodiamide antiviraux | |
| EP3532069A4 (fr) | Composés aryl-amide phosphodiamide antiviraux | |
| EP3446194A4 (fr) | Raccourcis d'application pour carplay | |
| ME03334B (fr) | Composés hétéroaryle d'inhibition de la kinase | |
| EP3609871A4 (fr) | Composés d'amide aryl cyclopropyl-amino-isoquinolinyl | |
| EP3562487A4 (fr) | Composés inhibiteurs des métalloenzymes | |
| DK3612519T3 (da) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| EP3464336A4 (fr) | Composés | |
| MA41169A (fr) | Composés antibactériens à large spectre d'activité | |
| EP3424868A4 (fr) | Mécanisme d'extension/contraction | |
| LT3867247T (lt) | Naujieji junginiai | |
| DK3548646T3 (da) | Novel korrosionshæmmende pakke | |
| EP3431808A4 (fr) | Butée d'arrêt | |
| IL269695A (en) | Compounds useful as inhibitors of alcat 1 | |
| HUE056928T2 (hu) | Új vegyületek | |
| DK3672941T3 (da) | Pyridylpyridonforbindelser | |
| MA52937A (fr) | Composés inhibiteurs d'oga |